This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the First Trust Materials AlphaDEX ETF (FXZ)?
by Zacks Equity Research
Sector ETF report for FXZ
Reasons Why You Should Hold Eastman Chemical Stock in Your Portfolio
by Anindya Barman
While EMN faces headwinds from weak demand in certain markets, it benefits from cost management, pricing actions and innovation.
BASFY & NIO Ink Deal to Boost Collaboration in Automotive Coatings
by Zacks Equity Research
BASFY and NIO sign an agreement to collaborate in the electric vehicle coatings sector.
DOW Stock Loses 27% in 6 Months: What Should Investors Do?
by Anindya Barman
While DOW benefits from investment in high-return projects and cost actions, weak end-market demand and declining estimates cast a pall on its prospects.
Eastman Chemical's Q4 Earnings Beat Estimates, Sales Lag
by Zacks Equity Research
EMN's Q4 earnings beat estimates driven by higher sales/volume mix and selling prices.
Compared to Estimates, Eastman Chemical (EMN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Eastman Chemical (EMN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Eastman Chemical (EMN) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Eastman Chemical (EMN) delivered earnings and revenue surprises of 18.35% and 0.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
U.S. Steel to Post Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Weaker selling prices and lower demand are likely to have hurt X's fourth-quarter results.
4 Chemical Stocks Poised to Outshine Q4 Earnings Estimates
by Anindya Barman
DuPont (DD), Eastman Chemical (EMN), Avient (AVNT) and Albemarle (ALB) are likely to have benefited from cost and productivity actions amid soft demand in Q4.
Going Into Q4 Earnings, is DOW Stock a Buy, a Sell, or Hold?
by Anindya Barman
While DOW is expected to have benefited from its cost and productivity actions, soft demand in certain markets is likely to have hurt its Q4 performance.
Eastman Chemical to Post Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
EMN is expected to have benefited from cost-cutting and productivity initiatives, as well as its innovation-driven growth strategy in Q4.
Cabot (CBT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cabot (CBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eastman Chemical (EMN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Eastman Chemical (EMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Eastman Chemical (EMN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Eastman Chemical (EMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DOW Trading Cheaper Than Industry: Should You Buy the Stock?
by Anindya Barman
While DOW benefits from investment in high-return projects and cost actions, weak end-market demand and declining estimates cast a pall on its prospects.
Reasons Why You Should Hold Eastman Chemical Stock in Your Portfolio
by Zacks Equity Research
While EMN faces headwinds from weak demand and inventory de-stocking in certain markets, it benefits from cost management, pricing actions and innovation.
Zacks Industry Outlook Highlights Air Products and Chemicals, DuPont de Nemours and Eastman Chemical
by Zacks Equity Research
Air Products and Chemicals, DuPont de Nemours and Eastman Chemical are part of the Zacks Industry Outlook article.
3 Diversified Chemical Stocks to Escape Industry Headwinds
by Anindya Barman
Demand softness in specific markets and the slowdown in China and Europe pose headwinds for the Zacks Chemicals Diversified industry. APD, DD and EMN are poised to navigate the industry challenges.
Here's Why You Should Retain Eastman Chemical Stock in Your Portfolio
by Zacks Equity Research
EMN benefits from its innovation-driven growth strategy and cost-management actions amid demand headwinds in certain markets.
DOW Stock Down 24% in 3 Months: Should You Buy the Dip?
by Anindya Barman
While DOW benefits from investment in high-return projects and cost actions, weak end-market demand and declining estimates cast a pall on its prospects.
Eastman Chemical Announces Hike in Dividend for 15th Straight Year
by Zacks Equity Research
This dividend increase reflects the board's confidence in EMN's steady earnings performance and strong cash flow generation.
Chemours (CC) Up 8.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto Eastman Chemical Stock for Now
by Zacks Equity Research
While EMN faces headwinds from weak demand and inventory de-stocking in certain markets, it benefits from cost management, pricing actions and innovation.
Eastman Chemical to Invest in Interlayers Production in Europe
by Zacks Equity Research
The investment will enhance EMN's supply capacity for Saflex PVB products in the Automotive Premiums sector.
Eastman Chemical's Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
EMN sees higher sales volume in Q3 due to the end of customer inventory de-stocking across most major end markets.